Deca Pharmaceuticals

Deciphera Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and delivering important new medicines to patients for the treatment of cancer. The company utilizes its proprietary switch-control kinase inhibitor platform to design highly specific and durable small molecule inhibitors that target the molecular switches of kinases. Their lead product, Qinlock (ripretinib), is approved for the treatment of fourth-line gastrointestinal stromal tumors (GIST). Deciphera's robust pipeline includes candidates like vimseltinib for tenosynovial giant cell tumors and DCC-3116, a first-in-class inhibitor of the ULK1/2 kinases designed to inhibit autophagy. In June 2024, the company was acquired by ONO Pharmaceutical, operating as a standalone subsidiary to continue its mission in precision oncology.